No history of cornea abnormalities
Significant abnormalities on ECG at Screening
Have major abnormalities documented by ECHO with Doppler:
Any of the following laboratory abnormalities:
Has ECG abnormalities that make QT interval corrected (QTc) evaluation difficult (e.g., severe morphologic abnormalities).
Significant screening ECG abnormalities.
Significant ECG abnormalities.
Patients excluded for laboratory abnormalities or performance score ONLY may be enrolled on the study with the approval of the PI or designee
Any of the following laboratory abnormalities:
Significant screening ECG abnormalities
Significant cardiac abnormalities
CNS abnormalities
Gastrointestinal abnormalities including but not limited to:
Has gastrointestinal abnormalities including:
Certain cardiac abnormalities or history
History or presence of bradydysrhythmia or conduction abnormalities
Patients with the following laboratory abnormalities:
Significant cardiac abnormalities;
Significant laboratory abnormalities;
Any of the following cardiac abnormalities or history
Subject has t(8;21), inv(16), t(16;16) or t(15;17) karyotype abnormalities.
Any of the following laboratory abnormalities:
Any of the following laboratory abnormalities:
Significant serum chemistry abnormalities
ECG abnormalities as defined by the protocol
Cardiac abnormalities
Cardiac abnormalities
Anyone with cardiac abnormalities or history
Any of the following laboratory abnormalities:
Patients with uncorrectable electrolyte abnormalities.
Patients must have a normal baseline ophthalmologic examination or have only clinically-insignificant abnormalities; patients with significant visual/ocular abnormalities identified during the baseline eye exam may be eligible after discussion with the study principal investigator (PI) and it is thought that the abnormalities pose no increased risk with study therapy
Any laboratory abnormalities, which in the opinion of the investigator, may put the subject at risk if participating in the study; for example:
De novo AML with karyotypic abnormalities characteristic of MDS: de novoAML must have cytogenetics with abnormalities per WHO.
No significant hematologic abnormalities
Any of the following laboratory abnormalities:
Have major abnormalities documented by echocardiography with Doppler
Any of the following laboratory abnormalities:
Significant ECG abnormalities.
Cardiac abnormalities
DONOR: No evidence of significant liver abnormalities
Any grade 4 laboratory abnormalities
Patient has any of the following cardiac abnormalities:
Any of the following laboratory abnormalities:
Cardiac abnormalities:
Cardiovascular abnormalities:
The history or evidence of following cardiac abnormalities:
Patients with any of the following hematologic abnormalities at baseline:
Patients with any of the following serum chemistry abnormalities at baseline:
PART I: Subjects with evidence of cardiac toxicity and Q wave abnormalities at baseline electrocardiography (ECG) will not be allowed to participate
PART II: Subjects with evidence of cardiac toxicity and Q wave abnormalities at baseline ECG will not be allowed to participate
Patients with any of the following hematologic abnormalities at baseline:
Patients with any of the following serum chemistry abnormalities at baseline:
Any of the following laboratory abnormalities:
Certain cardiac abnormalities.
Any of the following laboratory abnormalities:
History or evidence of cardiac abnormalities.
12-lead electrocardiogram (ECG) showing normal heart rhythm; note: if there are abnormalities, then the abnormalities must be deemed of no clinical significance
Any of the following laboratory abnormalities:
has following laboratory abnormalities
At least two manifestations drawn from at least two of the categories (clinical symptoms, laboratory abnormalities and radiographic abnormalities), which are at least possibly attributable to KICS and are not readily explicable from known medical conditions in the patient
LABORATORY ABNORMALITIES
RADIOGRAPHIC ABNORMALITIES
Any of the following laboratory abnormalities at Screening: